Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St rises as Anthropic's IPO filing sharpens focus on AI trade
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
| (NASDAQ: KURA) | Delayed: 9.67 +0.06 (0.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.61 | 52 Week High | $8.90 | |||
| Open | $9.73 | 52 Week Low | $2.50 | |||
| Day High | $9.84 | P/E | N/A | |||
| Day Low | $9.62 | EPS | $0.00 | |||
| Volume | 193,746 | |||||
